.jpg "Cytokinetics Inc (NASDAQ: CYTK)")
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Cytokinetics Inc (CYTK), with a price target of $21. The company’s shares closed on Friday at $6.85.
Pantginis said:
“Our thesis is based on three key areas at the company: (1) omecamtiv mecarbil program in heart failure with global partner Amgen (AMGN; not rated) and a projected significant boost in visibility this year (primary valuation contribution); (2) the volatile reldesmtiv program (ALS and SMA), which is expected to provide major answers this year; and (3).”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -20.2% and a 24.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics Inc with a $15.67 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.26 and a one-year low of $5.90. Currently, Cytokinetics Inc has an average volume of 395K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
